DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at ASM Microbe 2019 to be held June 20 – 24 in San Francisco, CA. “At Nabriva, we are committed to the...
Category: News
VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia
Malvern, PA, June 20, 2019 – VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US, 20 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it will present on its pipeline and strategy for the Company’s...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October 24, 2019 ~ MORRISTOWN, N.J., June 19, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development...
Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™ (fosfomycin) for injection
DUBLIN, Ireland, June 19, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it has submitted a Type A Meeting Request and Briefing Document to the U.S. Food and Drug Administration (FDA) to discuss the Complete...
Result of AGM
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Result of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 19 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that all resolutions proposed to shareholders at the Company’s Annual General Meeting (‘AGM’) held earlier today have been passed. The results of the proxy votes...
Increased BARDA Award and Option Exercise
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Summit Awarded $9.6M under Next Contract Option Total Committed BARDA Funding Now $53.6 Million Oxford, UK, and Cambridge, MA, US, 18 June 2019 – Summit Therapeutics plc...
Venatorx Pharmaceuticals to Present at ASM Microbe 2019
Malvern, PA, June 17, 2019 – Venatorx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. Venatorx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase...
Nabriva Therapeutics Applauds U.S. Senators for Introducing Legislation to Address the Serious Threat of Antimicrobial Resistance
MEDIA STATEMENT KING OF PRUSSIA, PA, June 12, 2019 – Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, issued the following statement regarding the recent introduction of the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019...